Jakeccc
Long

If you've been waiting to get long REGN, now is the time.

NASDAQ:REGN   REGENERON PHARMACEUTICALS
46 0 2
It got beaten so badly because of some analyst's note saying that REGN's blockbuster eye drug Eylea has been replaced by cheaper rival drugs. First, it was only rumored to be "10%" of total patients, secondly, its rheumatoid arthritis drug "sarilumab" that is under development with Sanofi             is showing promising signs and is now in phase 3. Overall, reaction is a little overblown IMO, we can expect a bounce from here.
Ideas Scripts Chart
United States
United Kingdom
India
España
Italia
Brasil
Россия
Türkiye
日本
한국
Home Stock Screener Economic Calendar How It Works Chart Features House Rules Moderators For the WEB Widgets Stock Charting Library Priority Support Feature Request Blog & News FAQ Help & Wiki Twitter
Private Messages Chat Ideas Published Followers Following Priority Support Public Profile Profile Settings Billing Sign Out